Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

To evaluate whether the sodium-glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). Patients with T2D ( = 84) (HbA 6.6 ± 0.5% [49 ± 10 mmol/mol], known disease duration 39 ± 27 months) were ran...

Celý popis

Podrobná bibliografia

Vydané v:	Diabetes care Ročník 43; číslo 2; s. 298
Hlavní autori:	Kahl, Sabine, Gancheva, Sofiya, Straßburger, Klaus, Herder, Christian, Machann, Jürgen, Katsuyama, Hisayuki, Kabisch, Stefan, Henkel, Elena, Kopf, Stefan, Lagerpusch, Merit, Kantartzis, Konstantinos, Kupriyanova, Yuliya, Markgraf, Daniel, van Gemert, Theresa, Knebel, Birgit, Wolkersdorfer, Martin F, Kuss, Oliver, Hwang, Jong-Hee, Bornstein, Stefan R, Kasperk, Christian, Stefan, Norbert, Pfeiffer, Andreas, Birkenfeld, Andreas L, Roden, Michael
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.02.2020
ISSN:	1935-5548, 1935-5548
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!